HRS-1893
Unknown / undisclosed
Evidence outlook · registrational
Hypertrophic Cardiomyopathy: registrational readout pending
Its supporting mid-stage studies have completed. The registry's posted readout date (2026-09) has passed without a status update. Check News for topline announcements.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Cardiac myosin (inhibitor) drugs
Aficamten, Mavacamten, Delocamten, Ulacamten. Compare all 5 Cardiac myosin (inhibitor) drugs
4 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Hypertrophic Cardiomyopathy: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| HRS-1893: this drug | Phase 3 | Undisclosed | Cardiac myosin (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Aficamten (Myqorzo) | Approved | Small molecule | Cardiac myosin (inhibitor) | Reliable signal | NCT05767346: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186) NCT05186818: Change From Baseline in pVO2 at Week 24 (Baseline to Week 24): Aficamten up to 20 mg 1.76 mL/kg/min (Standard Error 0.25) | Placebo to Match Aficamten 0.02 mL/kg/min (Standard Error 0.25) | |
| Mavacamten (Camzyos) | Approved | Small molecule | Cardiac myosin (inhibitor) | Partial signal | NCT04349072: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Sotagliflozin (Inpefa) | Phase 3 | Small molecule | SGLT1/2 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Delocamten | Phase 2(overall) | Small molecule | Cardiac myosin (inhibitor) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ninerafaxstat (IMB-101) | Phase 2 | Small molecule | Cardiac fatty-acid oxidation | not yet graded | No reviewed efficacy summary in this indication | |
| Ulacamten | Phase 2(overall) | Small molecule | Cardiac myosin (inhibitor) | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow HRS-1893 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.